Lotus Tissue Repair Announces Support of First International Patient Registry for Epidermolysis Bullosa (EB) and Formation of Clinical Advisory Board  
2/29/2012 6:26:06 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lotus Tissue Repair, Inc., a biotechnology company developing the first and only protein replacement therapy for the treatment of the rare genetic disorder dystrophic epidermolysis bullosa (DEB), today announced that it is providing grants to support the development and maintenance of the first international EB patient-reported registry, The registry was launched today by the DEB Research Association (DEBRA) International and DEBRA of America in conjunction with Rare Disease Day, as Lotus Tissue Repair participated in a Rare Disease Day event hosted by the Massachusetts Biotechnology Council at the Massachusetts State House.